4. Subjects, who are currently being treated with PD-1 or PD-L1 inhibitors Nivolumab or Atezolizumab and have achieved at least stable disease (SD), and who, in the judgment of their treating physicians, could benefit from the addition of DSP-7888 vaccine to improve or maintain their response.